Hologic (HOLX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Jan, 2026Executive summary
Entered into a Merger Agreement with Hopper Parent Inc. and Hopper Merger Sub Inc.; company to become a wholly owned subsidiary of Parent upon completion of the merger.
Definitive Proxy Statement filed and mailed to stockholders on December 23, 2025, regarding the proposed merger.
Forward-looking statements highlight risks related to regulatory approvals, stockholder vote, litigation, and potential impacts on business operations and CVR payments.
Voting matters and shareholder proposals
Stockholders are to vote on the proposed merger as outlined in the Definitive Proxy Statement.
Litigation seeks to enjoin the stockholder vote on the merger unless additional disclosures are made.
Board of directors and corporate governance
Information on directors and executive officers, including their interests in the merger, is disclosed in the Proxy Statement and recent SEC filings.
Latest events from Hologic
- Stockholders to vote on Blackstone/TPG acquisition as Q1 revenue rises 2.5%.HOLX
Proxy Filing - Revenue up 2.5% to $1.05B; merger with Blackstone/TPG on track for H1 2026 close.HOLX
Q1 2026 - Shareholders to receive $76 per share plus CVR in Blackstone/TPG acquisition, with key risks disclosed.HOLX
Proxy Filing - Strong Q4, 2025 growth guided at 4%, with innovation and M&A fueling future expansion.HOLX
7th Annual Evercore ISI HealthCONx Conference - Q4 revenue up 4.5% with strong segment growth; FY2025 targets 4% organic growth and margin gains.HOLX
Q4 2024 - International growth, recurring revenue, and innovation drive strong performance and future outlook.HOLX
Morgan Stanley 22nd Annual Global Healthcare Conference - Q3 revenue and EPS exceeded guidance, led by strong core segment growth and margin gains.HOLX
Q3 2024 - Strong growth, innovation, and global expansion drive robust financial and operational performance.HOLX
The 44th Annual William Blair Growth Stock Conference - Q2 revenue and non-GAAP EPS met guidance, but large impairments drove negative GAAP EPS.HOLX
Q2 2025